pLX307 MCL1 Citations (4)

Originally described in: MCL1 and DEDD promote urothelial carcinoma progression.
Hong AL, Guerriero JL, Doshi MB, Kynnap BD, Kim WJ, Schinzel AC, Modiste R, Schlauch AJ, Adam RM, Kwiatkowski DJ, Beroukhim R, Letai A, Rosenberg JE, Hahn WC Mol Cancer Res. 2019 Feb 18. pii: 1541-7786.MCR-18-0963. doi: 10.1158/1541-7786.MCR-18-0963. PubMed Journal

---

Articles Citing pLX307 MCL1

Articles
Integrated analysis of patient samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemia. Zhang H, Nakauchi Y, Kohnke T, Stafford M, Bottomly D, Thomas R, Wilmot B, McWeeney SK, Majeti R, Tyner JW. Nat Cancer. 2020 Aug;1(8):826-839. doi: 10.1038/s43018-020-0103-x. Epub 2020 Aug 18. PubMed
Virus-mediated inactivation of anti-apoptotic Bcl-2 family members promotes Gasdermin-E-dependent pyroptosis in barrier epithelial cells. Orzalli MH, Prochera A, Payne L, Smith A, Garlick JA, Kagan JC. Immunity. 2021 Jul 13;54(7):1447-1462.e5. doi: 10.1016/j.immuni.2021.04.012. Epub 2021 May 11. PubMed
Targeting anti-apoptotic pathways eliminates senescent melanocytes and leads to nevi regression. Kohli J, Ge C, Fitsiou E, Doepner M, Brandenburg SM, Faller WJ, Ridky TW, Demaria M. Nat Commun. 2022 Dec 23;13(1):7923. doi: 10.1038/s41467-022-35657-9. PubMed
Dual mTORC1/2 Inhibition Synergistically Enhances AML Cell Death in Combination with the BCL2 Antagonist Venetoclax. Satta T, Li L, Chalasani SL, Hu X, Nkwocha J, Sharma K, Kmieciak M, Rahmani M, Zhou L, Grant S. Clin Cancer Res. 2023 Apr 3;29(7):1332-1343. doi: 10.1158/1078-0432.CCR-22-2729. PubMed

If you have published an article using this material, please email us at to have your article added to this page.